

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation

Cyanocobalamin

Section	Indications
Antianaemia medicines .	Anaemias or other erythrocyte disorders

Dabigatran

Section	Indications
Medicines affecting coagulation Oral > Solid: 110 mg; 150 mg	Venous thromboembolism Other specified atrial fibrillation

Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism

Darbepoetin alfa

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease

Deferasirox

Section

Other medicines for haemoglobinopathies

Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

Indications

Therapeutic equivalent to [deferoxamine](#) pour

Thalassaemias

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Deferoxamine

Section

Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

Thalassaemias

Other specified sickle cell disorders or other haemoglobinopathies

Desmopressin

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)

Local > Nasal > Spray: 10 µg per dose (acetate)

Indications

Haemophilia A

Von Willebrand disease

Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) pour

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) pour

Other specified atrial fibrillation

Enoxaparin

Section

Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule

Indications

Acute ischaemic heart disease

Venous thromboembolism

Epoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

Epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

Epoetin theta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

Erythropoiesis-stimulating agents

Section

Antianaemia medicines

Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Indications

Anaemia due to chronic disease

Ferrous salt

Section

Antianaemia medicines

Oral > Liquid: 25 mg per mL iron (as sulfate)

Oral > Solid: 60 mg iron

Indications

Iron deficiency anaemia

Ferrous salt + folic acid

Section

Antianaemia medicines

Oral > Solid: 60 mg iron + 2.8 mg

Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

Indications

Iron deficiency anaemia

Iron deficiency anaemia

Spina bifida

Anencephaly or similar anomalies

Clefts of lip, alveolus or palate

Folic acid

Section

Antianaemia medicines

Oral > Solid: 1 mg tablet; 5 mg tablet

Oral > Solid: 400 µg

Indications

Folate deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

Cephalocele

Heparin sodium

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule

Indications

Acute ischaemic heart disease

Unstable angina

Venous thromboembolism

Hydroxocobalamin

Section

Antianaemia medicines

Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

Indications

Megaloblastic anaemia due to vitamin B12 deficiency

Hydroxycarbamide (hydroxyurea)

Section

Other medicines for haemoglobinopathies

Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Methoxy polyethylene glycol-epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

Nadroparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to enoxaparin pour

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin pour

Venous thromboembolism

Phytomenadione

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule

Oral > Solid: 10 mg tablet

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Haemorrhagic or haematological disorders of fetus or newborn

Protamine sulfate

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) pour

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) pour

Other specified atrial fibrillation

Tranexamic acid

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Haemorrhage, not elsewhere classified

Warfarin

Section

Medicines affecting coagulation

Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt);
0.5 mg (sodium salt)

Indications

Other specified diseases of arteries or arterioles

Cerebral ischaemic stroke due to embolic occlusion

Venous thromboembolism

Atrial fibrillation